(Q47197056)

English

Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice.

scientific article published on 22 July 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Vishal Patel

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Amit Joharapurkar

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Nirav Dhanesha

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Samadhan Kshirsagar

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Kartik Patel

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Rajesh Bahekar

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Mukul Jain

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

publication date

22 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Canadian Journal of Physiology and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

91

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1009-1015

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis?

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Alterations in energy balance following exenatide administration

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Suppression of weight gain by glucagon in obese Zucker rats

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

The FDA's assessment of two drugs for chronic weight management

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect.

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Glucagon: the effects of its excess and deficiency on insulin action.

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Potential use of exenatide for the treatment of obesity

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Pancreatic glucagon signals postprandial satiety

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Exenatide: a review from pharmacology to clinical practice

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Effect of chronic glucagon administration on lipoprotein composition in normally fed, fasted and cholesterol-fed rats.

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Mechanism by which metformin reduces glucose production in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

The epidemiology of obesity: the size of the problem

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Glucagon and regulation of glucose metabolism

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Dyslipidemia in obesity: mechanisms and potential targets

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Imipramine blocks ethanol-induced ASMase activation, ceramide generation, and PP2A activation, and ameliorates hepatic steatosis in ethanol-fed mice

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents.

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Anti-obesity drugs: past, present and future

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

DPP-IV-resistant, long-acting oxyntomodulin derivatives.

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Acute exercise increases triglyceride synthesis in skeletal muscle and prevents fatty acid-induced insulin resistance

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Effect of glucagon antibodies on plasma glucose, insulin and somatostatin in the fasting and fed rat.

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1139%2FCJPP-2013-0189

21 January 2018

Identifiers

10.1139/CJPP-2013-0189

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24289070%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47197056&oldid=1514209083"